Evaluates benralizumab's effects on responders and super-responders in Mexican patients, suggesting significant clinical benefits.
This is the first study in Mexico to evaluate the subgroup of super-responders to benralizumab who had clinical, laboratory and quality of life improvements. Besides the vast majority were responders and 64% super-responders at 12-months of treatment.
No takes yet. Share an insight, caveat, or question.
Ramírez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: